Tagged with access,

Pricing Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for withdrawing drug approval applications, cutting jobs, or delaying launches, claiming the new pricing regulations will substantially reduce revenues.    The…

Morocco Guillaume Recorbet, general manager of Servier in Morocco, explains Servier’s special status in the Moroccan pharma industry as a multinational company with a historic and extensive manufacturing footprint in the country, shares his three priorities to return the affiliate to the right track after a tough period following price cuts,…

Romania Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the new therapeutic direction that Lilly has taken by moving into rheumatology and dermatology. Additionally, he points to the change in…

Czech Republic Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before being able to enter the market.   While the timelines are still outside the defined framework, the situation is much…

Mexico Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global reshuffle has impacted Mexican operations, and the challenges inherent in bringing innovative treatments to what is a still-developing market.   A new set of rules is emerging in Mexican healthcare Fernando,…

UAE With a combined experience of over five decades in the pharmaceutical industry including senior executive roles at companies such as Merck and Janssen, Karim Smaira and Kamel Ghammachi have come a long way with Genpharm, the Dubai-based market access company they founded in 2012. After years of learning the ins…

Romania Dan Zaharescu, executive director of the Romanian Association of Pharmaceutical Manufacturers (ARPIM), shares his insights on market access, the need to reform pricing methodologies, the debate around the claw-back tax, his expectations for the newly appointed minister of health and prime minister, as well as his objectives for 2020.  …

UAE Georg Schroeckenfuchs, Novartis’ president for the Middle East and head of MEA cluster, is a 32-year veteran of the pharmaceutical industry and describes the company’s footprint within the MEA region, provides insights into its strategy of segmenting their markets into three categories. Furthermore, he discusses the company’s strategic priorities when…

Generics Arun Narayan of Medicines for Europe’s Value Added Medicines Group has been working to promote the benefits of value added medicines and how real-world evidence must be considered. In a recent interview with PharmaBoardroom he elaborated on what some countries are already doing to adopt Value Added Medicines and the…

Czech Republic Emelie Antoni joined AstraZeneca in Sweden 20 years ago, evolving in global, regional and local roles. Last year, she became country manager for Czech Republic & Slovakia, with an ambitious plan to triple revenues during her tenure. She lays down the pillars of her plan, discusses the evolving role of…

Generics Arun Narayan is the Chairman of the Value Added Medicines Sector Group at Medicines for Europe, in addition to serving as Head of Global Portfolio Strategy and Head of European Business Operations at Mylan. Narayan introduces compelling reasons why payers in Europe should consider Value Added Medicines, including cost savings…

Belgium The second edition of the European Cancer Forum was held in Brussels, Belgium on Tuesday, 29 January 2020. Hosted by MSD in collaboration with the European Cancer Patient Coalition (ECPC), Lung Cancer Europe (LuCE), and Digestive Cancers Europe (DiCE), the theme of this year’s event was “Towards A New Era…